HEB - VIDEO Update: Hemispherx Biopharma Inc. (NYSE MKT: HEB)

Hemispherx Biopharma, Inc. (NYSE MKT: HEB) is a specialty pharmaceutical company headquartered in Ocala, Florida and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders, according to the company’s website (see here: www.hemispherx.net).

SNNLive spoke with Thomas Equels, CEO of Hemispherx Biopharma, Inc. at the Planet MicroCap Showcase 2019 in Las Vegas, NV, and they discuss the following topics:

- Overview and history of Hemispherx Biopharma, Inc.

- Clinical development

- Update since our last interview (click here)

- What makes the company unique

- Competitive advantage

- Mr. Equels’ background

Hemispherx recently released its second quarterly update for its Ampligen in Immuno-Oncology program.

For more information about Hemispherx Biopharma, Inc., please visit: www.hemispherx.net

The interview may contain forward-looking statements about Hemispherx Biopharma, Inc. See Hemispherx Biopharma, Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.

Please read our full disclosure here.